Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial

被引：22
|
作者：
Jain, Nitin [1 ]
Basu, Sreyashi [2 ]
Thompson, Philip A. [1 ]
Ohanian, Maro [1 ]
Ferrajoli, Alessandra [1 ]
Pemmaraju, Naveen [1 ]
Cortes, Jorge E. [1 ]
Estrov, Zeev [1 ]
Burger, Jan A. [1 ]
Neelapu, Sattva S. [3 ]
Lopez, Wanda [1 ]
Thakral, Beenu [4 ]
Bueso-Ramos, Carlos E. [4 ]
Blando, Jorge [2 ]
O'Brien, Susan M. [5 ]
Kantarjian, Hagop M. [1 ]
Allison, James [2 ]
Keating, Michael [1 ]
Sharma, Padmanee [2 ]
Wierda, William G. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Immunotherapy Platform, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX USA
[5] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.59.59
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
59
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Phase I/II triple therapy study of umbralisib and ublituximab ("U2") combined with checkpoint inhibition in patients with rel/ref CLL and Richter's transformation
    Mato, Anthony
    Svoboda, Jakub
    Luning-Prak, Eline
    Schuster, Steven
    Tsao, Patricia
    Dorsey, Colleen
    Sarmasti, Lisa
    Becker, Pamela
    Brander, Danielle
    Geyer, Mark
    Park, Jae
    Deonarine, Isaac, Jr.
    King, Cara
    Morrigan, Beth
    Elwell, Jill
    Kennard, Kaitlin
    Roeker, Lindsey
    Zelenetz, Andrew
    Purdom, Michelle
    Paskalis, Dana
    Sportelli, Peter
    Miskin, Hari
    Weiss, Michael
    Shadman, Mazyar
    LEUKEMIA & LYMPHOMA, 2020, 61 : 20 - 21
  • [22] Revisiting Richter transformation in the era of novel CLL agents
    Petrackova, Anna
    Turcsanyi, Peter
    Papajik, Tomas
    Kriegova, Eva
    BLOOD REVIEWS, 2021, 49
  • [23] Richter transformation to aggressive plasmablastic neoplasm related to selection of a BTK-mutated clone in a patient with CLL/SLL treated by ibrutinib
    Aqil, Barina
    Kaur, Amandeep
    Ramos, Josean
    Sukhanova, Madina
    Ma, Shuo
    Gao, Juehua
    Lu, Xinyan
    Chen, Yi-Hua
    Chen, Qing
    LEUKEMIA & LYMPHOMA, 2023, 64 (01) : 242 - 245
  • [24] Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment
    Marvyin, Kristo
    Tjonnfjord, Eirik Brekka
    Breland, Unni Mathilde
    Tjonnfjord, Geir Erland
    BMJ CASE REPORTS, 2020, 13 (09)
  • [25] Rationale of a Phase II Trial of Nivolumab Combined with Anlotinib in Advanced NSCLC Previously Treated with Immunotherapy
    Han, B.
    Zhang, B.
    Shi, C.
    Gao, Z.
    Zhong, H.
    Xiong, L.
    Gu, A.
    Wang, W.
    Chu, T.
    Zhang, W.
    Wang, H.
    Zhang, X.
    Zhong, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S679 - S680
  • [26] Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones
    Woyach, Jennifer A.
    Ruppert, Amy S.
    Awan, Farrukh T.
    Jones, Jeffrey
    Andritsos, Leslie A.
    Waymer, Sharon
    Lozanski, Gerard
    Muthusamy, Natarajan
    Byrd, John C.
    BLOOD, 2016, 128 (22)
  • [27] Phase 1/2 trial of cirmtuzumab and ibrutinib: Planned analysis of phase 1 CLL cohorts.
    Choi, Michael Y.
    Wierda, William G.
    Lee, Hun Ju
    Tzachanis, Dimitrios
    Ianopulos, Xen
    Jezior, Deborah
    Breitmeyer, James Bradley
    Jamieson, Catriona H. M.
    Kipps, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
    Hodkinson, Brendan P.
    Schaffer, Michael
    Brody, Joshua D.
    Jurczak, Wojciech
    Carpio, Cecilia
    Ben-Yehuda, Dina
    Avivi, Irit
    Forslund, Ann
    Ozcan, Muhit
    Alvarez, John
    Ceulemans, Rob
    Fourneau, Nele
    Younes, Anas
    Balasubramanian, Sriram
    TRANSLATIONAL ONCOLOGY, 2021, 14 (01):
  • [29] Richter transformation in CLL: a meta-analysis of GCLLSG trials
    Al-Sawaf, Othman
    Robrecht, Sandra
    Bahlo, Jasmin
    Fink, Anna-Maria
    Cramer, Paula
    von Tresckow, Julia
    Lange, Elisabeth
    Kiehl, Michael
    Dreyling, Martin
    Rittgen, Matthias
    Duerig, Jan
    Fischer, Kirsten
    Stilgenbauer, Stephan
    Wendtner, Clemens
    Goede, Valentin
    Hallek, Michael
    Eichhorst, Barbara
    LEUKEMIA & LYMPHOMA, 2020, 61 : 98 - 100
  • [30] Efficacy of Ibrutinib Monotherapy in PreClinical Mouse Models of Richter Transformation: Ibrutinib Effectively Reduces the Incidence of Richter Transformation but Fails in Treating Transformed Lymphoma, Especially in Primary Lymphoid Tissue
    Chen, Shih-Shih
    Barrientos, Jacqueline
    Yan, Xiao-Jie
    Wirtz, Uwe
    Szafer-Glusman, Edith
    Rai, Kanti R.
    Chiorazzi, Nicholas
    BLOOD, 2021, 138 : 3708 - +
12345